Neulasta Biosimilars – Target Pipeline List 11/2018

Publisher: La Merie Publishing
Format: Word Table
Product Line:
Target Pipeline List
Product Code: LMTPL027
Release Date: November of 2018

150.00 €
Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Neulasta Biosimilars – Target Pipeline List 11/2018

Target: Granulocyte Colony Stimulating Factor (G-CSF) Receptor

This report provides a comprehensive overview of long-acting G-CSF receptor agonists as biosimilars of Neulasta (pegfilgrastim) from Amgen in regulated and in less regulated markets as well as of novel, potentially biosuperior, long-acting G-CSF receptor agonists for treatment of chemotherapy-induced neutropenia.

The world market of G-CSF products in the year 2017 was worth over US$ 5.5 bln, mostly due by global Neulasta sales of US$ 5.93 bln achieved by Amgen and Kyowa Hakko Kirin Pharma. Patent expiration of Neulasta has commenced in the European Union and numerous developers are ready to enter the attractive Neulasta market. The first Neulasta biosimilar products have been approved in Europe, the USA and in Canada. Neulasta biosimilars are already available on less regulated markets.

La Merie Publishing offers a low-cost product service providing information about active R&D projects for a given target in the format of Word tables. The Word document with the Table is delivered by e-mail within 24 hours after receipt of the confirmed order. Usually, delivery time is less than one hour if ordered during European business hours.

The Target Pipeline List in the Word table contains information about:

File: ID no. in proprietary database
Drug name: trade name, INN, drug code(s), trivial name
Target/MoA: mechanism of action
Class of compound: description of type of molecule, formulation, way and mode of administration, application device
Company: originator of molecule and licensee(s) with territories
Category: treatment modalities, i.e. antibody, protein, peptide, RNA, DNA, cells, vaccine, small molecule
Indication: medical indication evaluated in preclinical or clinical study, combination regimens
R&D Phase: from research to market with reference to indication/study
Message: last verified information about project with source and date of information and hyperlink leading to source of information

Research methodology:
Information about R&D projects is identified and retrieved from company publications including, but not limited to, press releases, presentations, website disclosures, SEC publications, regulatory documents, scientific abstracts and full papers, patent applications. Furthermore, public and proprietary databases are used including national and regional clinical trial databases, PubMed.


The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up